{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:36:21Z","timestamp":1773891381541,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,5,25]],"date-time":"2013-05-25T00:00:00Z","timestamp":1369440000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s00520-013-1831-6","type":"journal-article","created":{"date-parts":[[2013,5,24]],"date-time":"2013-05-24T05:38:21Z","timestamp":1369373901000},"page":"2351-2357","source":"Crossref","is-referenced-by-count":24,"title":["Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia"],"prefix":"10.1007","volume":"21","author":[{"given":"Jasem","family":"Al-Barrak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,25]]},"reference":[{"key":"1831_CR1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/1078155211436022","volume":"18","author":"D Bhattacharya","year":"2012","unstructured":"Bhattacharya D, Easthall C, Willoughby KA et al (2012) Capecitabine non-adherence: exploration of magnitude, nature, and contributing factors. J Oncol Pharm Pract 18:333\u2013342","journal-title":"J Oncol Pharm Pract"},{"key":"1831_CR2","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","volume":"28","author":"DL Hershman","year":"2010","unstructured":"Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120\u20134128","journal-title":"J Clin Oncol"},{"key":"1831_CR3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JOP.2010.000076","volume":"7","author":"J Hohneker","year":"2011","unstructured":"Hohneker J, Shah-Mehta S, Brandt PS (2011) Perspectives on adherence and persistence with oral medications for cancer treatment. J Oncol Pract 7:65\u201367","journal-title":"J Oncol Pract"},{"key":"1831_CR4","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","volume":"117","author":"AR Ibrahim","year":"2011","unstructured":"Ibrahim AR, Eliasson L, Apperley JF et al (2011) Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117:3733\u20133736","journal-title":"Blood"},{"key":"1831_CR5","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381\u20132388","journal-title":"J Clin Oncol"},{"key":"1831_CR6","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.bjc.6604758","volume":"99","author":"C McCowan","year":"2008","unstructured":"McCowan C, Shearer J, Donnan PT et al (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99:1763\u20131768","journal-title":"Br J Cancer"},{"key":"1831_CR7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3322\/caac.20004","volume":"59","author":"K Ruddy","year":"2009","unstructured":"Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56\u201366","journal-title":"CA Cancer J Clin"},{"issue":"suppl 3","key":"1831_CR8","first-page":"S1","volume":"6","author":"SN Weingart","year":"2008","unstructured":"Weingart SN, Brown E, Bach PB et al (2008) NCCN task force report: oral chemotherapy. J Natl Compr Cancer Netw 6(suppl 3):S1\u2013S14","journal-title":"J Natl Compr Cancer Netw"},{"key":"1831_CR9","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA et al (2003) For the IRIS investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u20131004","journal-title":"N Engl J Med"},{"key":"1831_CR10","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG et al (2006) For the IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"1831_CR11","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2010.0116","volume":"8","author":"GD Demetri","year":"2010","unstructured":"Demetri GD, von Mehren M, Antonescu CR et al (2010) NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Cancer Netw 8(suppl 2):S1\u2013S41, quiz S42\u2013S44","journal-title":"J Natl Compr Cancer Netw"},{"key":"1831_CR12","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2006.09.0183","volume":"25","author":"JY Blay","year":"2007","unstructured":"Blay JY, Le Cesne A, Ray-Coquard I et al (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25:1107\u20131113","journal-title":"J Clin Oncol"},{"key":"1831_CR13","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1470-2045(10)70222-9","volume":"11","author":"A Cesne Le","year":"2010","unstructured":"Le Cesne A, Ray-Coquard I, Bui BN et al (2010) For the French Sarcoma Group. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 11:942\u2013949","journal-title":"Lancet Oncol"},{"key":"1831_CR14","doi-asserted-by":"crossref","unstructured":"von Mehren M, Heinrich MC, Joensuu H et al. (2011) Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT\u2009+\u2009gastrointestinal stromal tumors (GIST). J Clin Oncol 29(15 suppl): Abstract 10016","DOI":"10.1200\/jco.2011.29.15_suppl.10016"},{"key":"1831_CR15","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1002\/cncr.25267","volume":"116","author":"JY Blay","year":"2010","unstructured":"Blay JY, von Mehren M, Blackstein ME (2010) Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer 116:5126\u20135137","journal-title":"Cancer"},{"key":"1831_CR16","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","volume":"373","author":"RP Dematteo","year":"2009","unstructured":"Dematteo RP, Ballman KV, Antonescu CR et al (2009) On behalf of the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097\u20131104","journal-title":"Lancet"},{"key":"1831_CR17","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.2012.347","volume":"307","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Eriksson M, Sundby Hall K et al (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307:1265\u20131272","journal-title":"JAMA"},{"key":"1831_CR18","unstructured":"National Comprehensive Cancer Network (NCCN) (2012) NCCN clinical practice guidelines in oncologyTM: Soft tissue sarcoma. National Comprehensive Cancer Network(R). Available at http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp . Accessed 21 Sep 2012"},{"key":"1831_CR19","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:5401\u20135411","journal-title":"Blood"},{"key":"1831_CR20","first-page":"215","volume":"16","author":"R Halpern","year":"2009","unstructured":"Halpern R, Barghout V, Zarotsky V et al (2009) Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal tumors. J Clin Outcomes Manag 16:215\u2013223","journal-title":"J Clin Outcomes Manag"},{"key":"1831_CR21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","volume":"86","author":"P Ganesan","year":"2011","unstructured":"Ganesan P, Sagar TG, Dubashi B et al (2011) Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86:471\u2013474","journal-title":"Am J Hematol"},{"key":"1831_CR22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12185-011-0838-3","volume":"93","author":"C Yoshida","year":"2011","unstructured":"Yoshida C, Komeno T, Hori M et al (2011) Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia. Int J Hematol 93:618\u2013623","journal-title":"Int J Hematol"},{"key":"1831_CR23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","volume":"26","author":"EQ Wu","year":"2010","unstructured":"Wu EQ, Johnson S, Beaulieu N et al (2010) Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 26:61\u201369","journal-title":"Curr Med Res Opin"},{"key":"1831_CR24","unstructured":"Ray-Coquard IL, Bin Bui N, Adenis A (2010) et al. Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study. J Clin Oncol 28(15 suppl): Abstract 10032"},{"key":"1831_CR25","first-page":"1407","volume":"31","author":"F Mazzeo","year":"2011","unstructured":"Mazzeo F, Duck L, Joosens E et al (2011) Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. Anticancer Res 31:1407\u20131409","journal-title":"Anticancer Res"},{"key":"1831_CR26","doi-asserted-by":"crossref","unstructured":"Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J Clin Oncol 24(18S suppl): Abstract 6119","DOI":"10.1200\/jco.2006.24.18_suppl.6119"},{"key":"1831_CR27","doi-asserted-by":"crossref","unstructured":"Feng W, Henk H, Thomas S et al. (2006) Compliance and persistency with imatinib. J Clin Oncol 24(18S suppl): Abstract 6038","DOI":"10.1200\/jco.2006.24.18_suppl.6038"},{"key":"1831_CR28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487\u2013497","journal-title":"N Engl J Med"},{"key":"1831_CR29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ctrv.2010.10.001","volume":"37","author":"M Mehren von","year":"2011","unstructured":"von Mehren M, Widmer N (2011) Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 37:291\u2013299","journal-title":"Cancer Treat Rev"},{"key":"1831_CR30","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626\u2013632","journal-title":"J Clin Oncol"},{"key":"1831_CR31","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"AJ Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296\u20131310","journal-title":"Clin Ther"},{"key":"1831_CR32","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","volume":"35","author":"L Eliasson","year":"2011","unstructured":"Eliasson L, Clifford S, Barber N et al (2011) Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 35:626\u2013630","journal-title":"Leuk Res"},{"key":"1831_CR33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00277-011-1359-0","volume":"91","author":"S J\u04e7nsson","year":"2012","unstructured":"J\u04e7nsson S, Olsson B, S\u04e7derberg J et al (2012) Good adherence to imatinib therapy among patients with chronic myeloid leukemia\u2014a single-center observational study. Ann Hematol 91:679\u2013685","journal-title":"Ann Hematol"},{"key":"1831_CR34","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2354.2010.01212.x","volume":"20","author":"V Regnier Denois","year":"2011","unstructured":"Regnier Denois V, Poirson J, Nourissat A et al (2011) Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. Eur J Cancer Care (Engl) 20:520\u2013527","journal-title":"Eur J Cancer Care (Engl)"},{"key":"1831_CR35","doi-asserted-by":"crossref","unstructured":"O'Brien SG, Guilhot F, Goldman JM et al. (2008) International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood (ASH Annual Meeting Abstracts) 112: Abstract 186","DOI":"10.1182\/blood.V112.11.186.186"},{"key":"1831_CR36","unstructured":"Baker LH, Rankin CJ, Blanke CD et al. (2011) Long-term follow-up of SWOG S0033, a phase III randomized intergroup trial assessing imatinib mesylate at two dose levels in patients with metastatic and\/or unresectable gastrointestinal stromal tumors (GIST). Connective Tissue Oncology Society Annual Meeting Abstracts: Abstract 24"},{"key":"1831_CR37","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879\u2013894","journal-title":"Clin Pharmacokinet"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1831-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-013-1831-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1831-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T20:29:53Z","timestamp":1645561793000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-013-1831-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,25]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["1831"],"URL":"https:\/\/doi.org\/10.1007\/s00520-013-1831-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,25]]}}}